EUVIMEDEUVIMED entdecken
Klinische Studie (Phase I)Multizentrische StudieRandomisierte kontrollierte StudieOpen Access · CC BY-NC-ND 4.0

Talazoparib Formulation Bridging in Cancer Patients—Challenges and the Critical Role of Model‐Informed Drug Development in Approval Despite Failed Bioequivalence

Diane Wang, Cathy Cen Guo iD, Xizhe Gao, Yibo Wang, Yanke Yu, Anna Plotka, Mohamed Elmeliegy, Haihong Shi, Samantha Johnson, Liza DeAnnuntis iD, Justin Hoffman

CPT: Pharmacometrics & Systems Pharmacology · 2026

DOI: 10.1002/psp4.70157 ↗

Kurz gefasst

Klinische Studie (Phase I) in der Zeitschrift CPT: Pharmacometrics & Systems Pharmacology, 2026. Verfasst von Diane Wang und 10 weiteren Autor:innen. Beteiligte Einrichtung: Pfizer Inc., La Jolla, California, USA. Hauptthemen laut MEDLINE: Antineoplastic Agents, Models, Biological, Neoplasms, Phthalazines. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 19 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Talazoparib is a poly(ADP‐ribose) polymerase inhibitor approved for the treatment of breast and prostate cancer. Commercialization of a soft gelatin capsule (SGC) formulation developed post‐approval required a bioequivalence (BE) and food effect (FE) study to bridge SGC with the initial commercial hard capsule (HC) formulation. Study execution and meeting BE criteria are challenging due to high variability in C max , potentially higher C max for SGC based on dissolution data, and the need to perform BE/FE assessment at steady state in cancer patients. Model‐informed drug development (MIDD) was used to facilitate an efficient/feasible study design. Semi‐mechanistic pharmacokinetic (PK)/pharmacodynamic (PD) modeling and simulations showed that AUC, instead of C max , drove hematologic events, the main side effects of talazoparib. This supported a BE study powered for AUC equivalence only. Population PK simulation showed that following a 28‐day treatment in the first period, 14 days in subsequent periods is sufficient for steady‐state BE/FE assessments. Study results showed AUC met BE criteria while C max was 37% higher for SGC relative to HC, which was deemed not clinically significant based on the PK/PD model. FE on SGC formulation was consistent with FE on HC formulation reported previously. The safety profile of the two formulations was generally consistent with the known safety profile. The totality of data (AUC equivalence, lack of impact of C max on safety, observed safety data) supported bridging of the two formulations although C max failed to meet BE criteria. MIDD was critical in study design optimization and supported approval of the SGC formulation. Trial Registration: ClinicalTrials.gov Identifier: NCT04672460

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antineoplastic AgentsModels, BiologicalNeoplasmsPhthalazinesPoly(ADP-ribose) Polymerase InhibitorsAdultAgedFemaleHumansMaleMiddle AgedArea Under CurveBreast NeoplasmsCapsulesComputer SimulationDrug ApprovalDrug DevelopmentFood-Drug InteractionsTherapeutic Equivalency

Stichwörter der Autor:innen

MIDDPARP inhibitorPK/PD modelingbioequivalencecancer

Substanzen

Antineoplastic AgentsCapsulesPhthalazinesPoly(ADP-ribose) Polymerase Inhibitorstalazoparib

Autor:innen und Institutionen

  • Pfizer Inc., La Jolla, California, USA.
  • Pfizer Inc., Collegeville, Pennsylvania, USA.
  • Pfizer Inc., Groton, Connecticut, USA.
  • Pfizer R&D UK Ltd., Sandwich, Kent, UK.

ORCID-Profile: Cathy Cen Guo, Liza DeAnnuntis

Zitieren

APA

Wang, D., Guo, C. C., Gao, X., Wang, Y., Yu, Y., Plotka, A., Elmeliegy, M., Shi, H., Johnson, S., DeAnnuntis, L., & Hoffman, J. (2026). Talazoparib Formulation Bridging in Cancer Patients—Challenges and the Critical Role of Model‐Informed Drug Development in Approval Despite Failed Bioequivalence. CPT: Pharmacometrics & Systems Pharmacology. https://doi.org/10.1002/psp4.70157

Vancouver

Wang D, Guo CC, Gao X, Wang Y, Yu Y, Plotka A, et al. Talazoparib Formulation Bridging in Cancer Patients—Challenges and the Critical Role of Model‐Informed Drug Development in Approval Despite Failed Bioequivalence. CPT: Pharmacometrics & Systems Pharmacology. 2026. doi:10.1002/psp4.70157

BibTeX
@article{Wang2026,
  author = {Wang, Diane and Guo, Cathy Cen and Gao, Xizhe and Wang, Yibo and Yu, Yanke and Plotka, Anna and Elmeliegy, Mohamed and Shi, Haihong and Johnson, Samantha and DeAnnuntis, Liza and Hoffman, Justin},
  title = {Talazoparib Formulation Bridging in Cancer Patients—Challenges and the Critical Role of Model‐Informed Drug Development in Approval Despite Failed Bioequivalence},
  journal = {CPT: Pharmacometrics & Systems Pharmacology},
  year = {2026},
  doi = {10.1002/psp4.70157}
}
Kostenlos starten →